Senef AS

CEO, Investor & Expert in Strategy & Logistics solutions, Consulting, Concert & Events, Booking, Management

[Elon Musk @elonmusk]

SpaceX IPO info

[The Market Ear @themarketear]

North American M&A announcements increased in May to $315 bn, up from $286 bn in April
https://t.co/xuaMIvLob7

[Senef AS @SenefLiveEvents]

What that mean Payoneer 🤔 $PAYO

[OptionsFlowBoss @OptionsFlowBoss]

$PAYO

OI changes

[Senef AS @SenefLiveEvents]

$GMAB Genmab Up potential from this level are 60-65% if the results are good… Consesus of Analysts are Buy with average price of 38.31$ $XBI $IBB

[Senef AS @SenefLiveEvents]

$GMAB buy now or cry later 🙃 -> -Truist assumes Genmab coverage with a Buy rating on pipeline

- Highlights company's three lead assets with up to seven key readouts expected in 2026

-Sets $40 target $XBI $IBB $JNJ

[Adam May @A_May_MD]

So $ABVX went from ~$180 after hours to ~$69 on the slide below, which people have (misguidedly IMO) interpreted as a cancer risk in the high dose arm.

This looks very much like noise - 2 cases (one each, a rate of 0.5%) of the 2 most common cancers in the world (breast and prostate). Zero cases in the low dose arm. NMSC is a throwaway side note and almost always age related - as they noted they *were* in this case. The only thing to adjudicate is the prostate and breast cases.

They also noted ZERO cases in the long term extension study from phase 2, which consisted of well over 100 patients and has had some patients on drug for 7+ years, ALL of them on drug for >2 years.

2 cases (again, 1 each) of the 2 most common cancers in the world among all those patients (P2+P3) over all those years. This is noise.

Let's say you *don't* think this is noise for the high dose...

Well, then it's a good thing that the low dose showed zero malignancy signal vs placebo and *still* came in with efficacy vastly above the market's expectations (39% delta vs 40% for the high dose).

The low dose with 39.3% delta and no cancer signal is right there with the (previously) highest reported efficacy drug, Rinvoq...Except, Rinvoq has a black box warning that has *5* bullet points:
-Serious infections "leading to hospitalization or death"
-Higher rate of all cause mortality "including sudden cardiovascular death"
-MALIGNANCIES "including lymphomas and lung cancers"
-Higher rate of MACE (including heart attacks and strokes)
-Thrombosis (including pulmonary embolism)

So, let's say you do think this gets a black box warning for malignancy risk (even despite all the notes above, and the fact that the low dose had zero cases of non-NMSC malignancy and was balanced with placebo on NMSC)...

...then you are looking at a WORST CASE scenario of 1 bullet on a black box warning versus *5* for Rinvoq (and the other JAK inhibitors).

The 2nd highest clinical remission delta for a non black box warning drug ever is...Entyvio at 26%....

So you have 2 JAKi with 5 black box warning "points" and remission deltas of 39.8% (Rinvoq) and 30% (Xeljanz).

Again, WORST case, $ABVX gets 1 black box warning "point" despite all the evidence that this is just noise and had 39.3% and 40.3% remission delta.

Want something without a black box? You're looking at 20-26% delta. And again, that's *if* this is actually something the FDA doesn't think is noise. You've got the 25mg dose with literally zero signal versus placebo and 7+year P2 dataset saying zero signal as well with many of those patients having been on higher than 25 mg doses.

At $70 AH this is a $6B company? Absurd from my perspective. At worst this is the most efficacious drug in the industry with a black box warning 1/5th as bad as the JAKis that do big numbers in this disease at WORST.

[Senef AS @SenefLiveEvents]

$MRVL not bad… Keep an eye

[First Squawk @FirstSquawk]

MARVELL TECHNOLOGY SHARES JUMP 21.1% PREMARKET AFTER NVIDIA CEO JENSEN HUANG CALLS CO THE NEXT TRILLION DOLLAR COMPANY

[Senef AS @SenefLiveEvents]

Buyout or not buyout 🤔 $ABVX

Abivax (Euronext Paris:ABVX / NASDAQ:ABVX) shares initially rose 20% after-hours Monday following positive Phase 3 results for its ulcerative colitis drug obefazimod. However, shares have since reversed course and are now down 40%.
The Phase 3 ABTECT maintenance trial met its primary endpoint, with both 25 mg and 50 mg once-daily doses achieving clinical remission rates of 50.8% and 51.3% respectively at Week 44, compared to 10.4% for placebo. The placebo-adjusted clinical remission rates were 39.3% for the 25 mg dose and 40.3% for the 50 mg dose.

[Senef AS @SenefLiveEvents]

$GMAB buy now or cry later 🙃 -> -Truist assumes Genmab coverage with a Buy rating on pipeline

- Highlights company's three lead assets with up to seven key readouts expected in 2026

-Sets $40 target $XBI $IBB $JNJ

[Stockwatch DK @StockwatchDK]

$GMAB UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations.

After the conference call afterwards, UBS notes that attention focused on two issues: namely whether the interim analysis of Epkinly's Phase 3 trial in first-line diffuse large B-cell lymphoma had taken place, and concerns about the potential impact of increasing the sample size in the Phase 3 study of Petosemtamab in head and neck cancer.

UBS believes there was no additional information during this call, but that the drop in the stock price on Friday likely reflects market nervousness in the face of multiple major catalysts expected this year.

UBS specifies that it is not changing its revenue forecasts, but has adjusted the operating profit forecasts in order to include the amortization costs related to the acquisition of Merus.

[The Wall Street Journal @WSJ]

Uber has emerged as the biggest shareholder in Delivery Hero after making sizable stake purchases in recent weeks. https://t.co/OSN7H9Q2NE

[Bloomberg @business]

Bain, LY Said to Offer to Buy Kakaku, Rivaling EQT Takeover Bid https://t.co/LBoB1GAlet

[Stockwatch DK @StockwatchDK]

$GMAB UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations.

After the conference call afterwards, UBS notes that attention focused on two issues: namely whether the interim analysis of Epkinly's Phase 3 trial in first-line diffuse large B-cell lymphoma had taken place, and concerns about the potential impact of increasing the sample size in the Phase 3 study of Petosemtamab in head and neck cancer.

UBS believes there was no additional information during this call, but that the drop in the stock price on Friday likely reflects market nervousness in the face of multiple major catalysts expected this year.

UBS specifies that it is not changing its revenue forecasts, but has adjusted the operating profit forecasts in order to include the amortization costs related to the acquisition of Merus.

[Senef AS @SenefLiveEvents]

@risenfit Yes but price don’t move a lot 😢

[Senef AS @SenefLiveEvents]

GS give a upgrade price for Genmab $GMAB 2300K Buy - Earning are done and not bad after all… https://t.co/Gzw6KqY05r $NVO $JNJ $XBI

[Senef AS @SenefLiveEvents]

@strau22 @wallstlobo Interesting…

[Senef AS @SenefLiveEvents]

And what about $OCUL 🤔 ? $BAYN.DE

[WSJ Business News @WSJbusiness]

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion https://t.co/aWxTzI7Vei

[Senef AS @SenefLiveEvents]

@wallstlobo Mmmm when ?

[Senef AS @SenefLiveEvents]

It’s time to shine Novo $NVO next -> Genmab $GMAB #biotech #bigpharma $IBB $XBI

[Bloomberg @business]

Novo Nordisk’s new Wegovy pill helped fuel sales in the first quarter as the drugmaker said this year’s declines won’t be as bad as initially expected https://t.co/rFgJbvixk2

[Senef AS @SenefLiveEvents]

@Pharmdca Keep an eye on $GMAB 😉

[Senef AS @SenefLiveEvents]

$GME Gamestop is offering $125 per share in a combination of stock and cash, a 46 percent premium over the average stock price since it began acquiring shares in eBay $EBAY on February 4, it said in a release.

#memestock :)

https://t.co/7OB57QWrJ9

[Bio Stocks™ @BioStocks]

Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB

If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech

https://t.co/Lcjadh7voY